Shimada et al (2005) demonstrated that phosphorylation status of FADD is associated with prostate cancer progression, using immunohistochemistry. Our present clinicopathological study demonstrated expression of phosphorylated forms of JNK and FADD to be significantly reduced in cancer cells with lymph node metastasis. Further, we provided evidence that overexpression of dephosphorylated FADD upregulates invasion activity of cancer cells in vitro. This evidence concerns the gene FADD and prostate carcinoma.